The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2015: Volume 20/ Issue 20 Article 5
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 20, Issue 20, 21 May 2015
Review articles
The challenge of West Nile virus in Europe: knowledge gaps and research priorities
  1. Fondazione Edmund Mach, Research and Innovation Centre, Department of Biodiversity and Molecular Ecology, San Michele all’Adige (TN), Italy
  2. These authors contributed equally to this manuscript
  3. Centro de Investigación en Sanidad Animal, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Valdeolmos, Spain
  4. Department of Molecular Medicine, University of Padova, Padova, Italy
  5. Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", Brescia, Italy
  6. Wetland Ecology Department, Doñana Biological Station (CSIC), Seville, Spain
  7. Erasmus Medical Centre, Rotterdam, the Netherlands
  8. Viroscience lab, Erasmus Medical Centre, Rotterdam, The Netherlands
  9. Istituto Zooprofilattico Sperimentale della Lombardia e de L’Emilia Romagna, Brescia, Italy
  10. Institute of Virology, University of Veterinary Medicine Vienna, Vienna, Austria
  11. Department of Microbiology and Immunology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman
  12. Institut Pasteur, Paris, France
  13. Laboratory of Gene Therapy, Department of Nutrition, Genetics and Ethology, Faculty of Veterinary Medicine, Ghent University, Belgium
  14. Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany
  15. Arbovirus and imported viral diseases, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, Spain

Citation style for this article: Rizzoli A, Jiménez-Clavero MA, Barzon L, Cordioli P, Figuerola J, Koraka P, Martina B, Moreno A, Nowotny N, Pardigon N, Sanders N, Ulbert S, Tenorio A. The challenge of West Nile virus in Europe: knowledge gaps and research priorities. Euro Surveill. 2015;20(20):pii=21135. Article DOI:
Date of submission: 02 July 2014

West Nile virus (WNV) is continuously spreading across Europe, and other continents, i.e. North and South America and many other regions of the world. Despite the overall sporadic nature of outbreaks with cases of West Nile neuroinvasive disease (WNND) in Europe, the spillover events have increased and the virus has been introduced into new areas. The high genetic diversity of the virus, with remarkable phenotypic variation, and its endemic circulation in several countries, require an intensification of the integrated and multidisciplinary research efforts built under the 7th Framework Programme of the European Union (FP7). It is important to better clarify several aspects of WNV circulation in Europe, including its ecology, genomic diversity, pathogenicity, transmissibility, diagnosis and control options, under different environmental and socio-economic scenarios. Identifying WNV endemic as well as infection-free areas is becoming a need for the development of human vaccines and therapeutics and the application of blood and organs safety regulations. This review, produced as a joint initiative among European experts and based on analysis of 118 scientific papers published between 2004 and 2014, provides the state of knowledge on WNV and highlights the existing knowledge and research gaps that need to be addressed with high priority in Europe and neighbouring countries.


West Nile virus (WNV) is an African flavivirus originally maintained in sylvatic cycles mostly between mosquitoes and birds. Since the 1950s, there has been evidence of circulation outside its original ecological niches [1]. Relatively large outbreaks of West Nile neuroinvasive disease (WNND) have been recorded in humans and/or horses in an increasing number of areas. WNV infections have been identified in many European and Mediterranean countries (Figure 1) [1,2]. The increasing incidence of WNND, the appearance of new foci, and the endemic virus circulation in temperate areas have promoted research and innovation efforts financially supported by the European Commission (EC) under the 7th Framework Programme (FP7). However, knowledge gaps remain on several important aspects of virus ecology, biology, and pathogenicity. Together with the lack of safe vaccines and specific therapeutic treatments for humans, this limits our ability to efficiently predict, prevent and control WNV infections, with increasing costs due to the needs of guarantee the safety of blood transfusion and organ donation [3]. There are also rising problems associated with the loss in efficacy and increased resistance to many commercial insecticidal products used to suppress mosquito populations [4]. This requires the intensification of research efforts for emerging vector-borne infections, such as those caused by WNV and other flaviviruses, and the maintenance of the existing research capacity.

Figure 1. Cumulative number of human cases of West Nile virus infection in Europe and neighbouring countries, 2010 to 2013

Therefore, the coordinators and representative members of four EC FP7 European funded projects on WNV and other mosquito-borne viral diseases (EuroWestNile, EDENext, Wings, Vectorie) met in Madrid on several occasions to review and discuss WNV knowledge advances and identify research gaps to be addressed, under a ‘One Health’ perspective, with high priority.


The expert group integrated their expert knowledge and opinion with a scientific literature review. Following a search in the databases ISI Web of Knowledge and PubMed, using defined qualifiers for the viral infection [(WNV)], the disease [(WNND)], host [(humans], [birds], [horses)], geographical location [(Africa], [Europe], [Mediterranean basin)] and issue [(virology], [genomics], [epidemiology], [ecology], [pathology], [diagnostics], [vaccine], [control], [review]). In the search, the period of publication was limited to publications from January 2004 to October 2014. Inclusion criteria were based on title, abstract and year of publication, leading, if relevant to the above mentioned qualifiers, to retrieval and analysis of the full paper. Exclusion criteria were based on the year of publication and on the novelty of the information provided choosing those most up to date on the same subject and those including the previous in the reference list. Only articles with the latest findings on a specific subject were included and those older than the period covered were discarded.

A total of 118 scientific publications were then chosen among the 513 initially retrieved.

Epidemiology of West Nile virus in Europe and neighbouring countries

Circulating West Nile virus strains
The re-emergence of WNV in Europe and neighbouring countries after 1990 led to an intensified surveillance for WNV infection not only in humans, but also in horses, birds, and mosquitoes in several areas. This has resulted in the detection and/or isolation of many different strains of WNV, eventually classified as up to seven (nine) different genetic lineages [5-10] (Table 1, Figure 2 A-C). There is a growing number of WNV lineages and to address inconsistent numbering in the literature we suggest in Table 1 and Figure 2 a harmonised WNV lineage numbering.

Table 1. Overview of West Nile virus lineages and suggested lineage numbering

Figure 2. Suggested harmonised West Nile virus lineage numbering based on phylogenetic analysisa 

The most widespread WNV lineages include lineage 1, clade 1a, belonging to the Mediterranean and former eastern European subtype, and lineage 2, which emerged in central Europe in 2004, and dispersed from Hungary to the eastern part of Austria and to southern European countries [11,12]. Following an independent introduction, another lineage 2 strain was detected in 2004 in Rostov Oblast, southern Russia [13]; subsequently, this virus strain has been responsible for outbreaks of WNND in Volgograd Oblast southern Russia since 2007, and in Romania since 2010 [14,15]. Phylogenetic analyses revealed that all European WNV lineage 1 and 2 strains are derived from a limited number of independent introductions, most likely from Africa, followed by local spread and evolution [5,15-20]. Other lineages identified but not associated so far with human or animal diseases include WNV lineage 3, also known as Rabensburg virus, first isolated in 1997 in South Moravia (Czech Republic) in Culex pipiens and Aedes rossicus mosquitoes in Czech Republic, and named after the nearby Austrian city of Rabensburg [6], WNV lineage 4a, Krasnodar virus, first detected in a Dermacentor tick and then in mosquitoes and frogs in southern Russia [7], putative WNV lineage 4b, identified in 2010 mosquitoes in southern Spain [8], and lineage 4c detected in Uranotaenia unguiculata mosquitoes in Austria in 2013 [9].

In recent years, the availability of whole WNV genome sequences of European origin, necessary for diagnostic and molecular epidemiology and for better refining WNV taxonomic classification, has improved. A WNV strain bank and associated large genomic database has been built by the EuroWestNile consortium to facilitate this availability. The biobank and database are now available for the scientific community (

Analyses of full genome sequence data have shown that the virus, notwithstanding its high genetic stability, can adapt to new ecological niches through mutation and selection events [21]. In addition to this plasticity, the presence of other flaviviruses infecting mosquitoes, birds and humans, may have important consequences not only for WNV ecology, epidemiology and pathogenicity, but also for diagnostics, surveillance and control strategies [22].

West Nile lineages and human cases
Most humans infected with WNV remain asymptomatic and only approximately 20–40% develop symptoms. The vast majority of clinical manifestations are a mild influenza-like illness, defined as West Nile fever (WNF); severe neuroinvasive disease (WNND) occurs only in <1% of the infected patients. WNND usually encompasses three different syndromes: meningitis, encephalitis, and acute flaccid paralysis [2 and references herein]. According to the European Centre for Disease Prevention and Control (ECDC), the total number of WNND cases reported from 2010 to 2013 was particularly high in Greece, with 262 cases of WNND notified in 2010 (incidence 2.34/100,000), 100 in 2011 (incidence 0.90/100,000), 161 in 2012 (incidence 1.45/100,000), and 86 in 2013 (incidence 0.78/100,000) (unpublished data).

WNV lineage 2 strains belonging to the Hungarian clade were responsible for the outbreaks in Greece [23,24] and in other central European countries, including Serbia [25-27], where 71 (incidence 0.98/100,000) and 302 (incidence 4.91/100,000) human infections were notified in 2012 and 2013, respectively. Autochthonous human cases of infection with this WNV strain were identified in recent years in Hungary, Austria [28], Croatia [29,30], Albania, the former Yugoslav Republic of Macedonia, Kosovo* and Montenegro. Closely related WNV lineage 2 strains of the same Hungarian clade have also been detected in Italy since 2011 [31-33], leading to a large outbreak with 69 notified human infections (incidence 0.12/100,000) in 2013 [34], and in the Czech Republic in 2013 [35]. The epidemiological situation in Italy is, however, more complex than in other countries [36]. WNV lineage 1 strains of the western Mediterranean subtype, including the Livenza strain that caused an outbreak in the area in northern Italy in 2012 [19,37] that was later affected by the WNV lineage 2 strain in 2013, have been autochthonous in Italy and co-circulate with WNV lineage 2. WNV lineage 1 strains classified as western Mediterranean subtype circulated also in southern Spain [20], where sporadic human infections were reported in 2010.

In Turkey, human cases of WNV infection were reported in 2010 (47 cases, incidence 0.06/ 100,000) and in 2011 (five cases, incidence 0.01/100,000) [38]. WNV strains obtained between 2011 and 2013 from humans, horses and mosquitoes across Turkey proved to be closely related to ‘old’ lineage 1 strains from sub-Saharan Africa [39]. Israel, a highly WNV-affected Mediterranean country [40], noted over 100 cases diagnosed in 2010, 33 in 2011, 83 in 2012, and 63 in 2013 (incidence rates per 100,000 not available) [40]. Finally, the southern Russian/Romanian WNV lineage 2 strain [15] has led to large outbreaks of WNND in humans in southern Russia in each season from 2010 to 2013 (419 cases in 2010, 137 in 2011, 447 in 2012, and 177 in 2013, incidences rates per 100,000 not available), and in 2010 Romania, when 57 human infections (incidence 0.28/100,000) were identified [14].


Mosquito vectors
Several mosquito genera are competent for WNV transmission; however, mosquitoes belonging to the Culex pipiens complex and their hybrids play a central role in modulating the virus circulation and the seasonal shifts among birds and humans [41]. In addition to Cx. pipiens, Cx. perexiguus and Cx. modestus have been identified as important WNV vectors [42], while the role of other species, including the Aedes albopictus, needs to be better evaluated.

Introduction, transmission and spread
Introduction of WNV into new areas is generally considered to be initiated by migratory birds while residential and synanthropic birds may contribute to virus dispersal into larger areas, as well as to the following establishment and spread in certain areas [43,44]. However, the relative importance of dispersal of WNV through infected mosquitoes rather than by infected birds is unknown. The introduction event may or may not be followed by an amplification phase depending on several coincidental factors, ranging from the birds’ and vectors’ competence, abundance and community assembly, to the local environmental condition including climate and landscape features [45-47]. One recognised important factor for WNV amplification and the following risk of transmission to humans is the feeding behaviour and host selection by the mosquito vectors. Based on preliminary research carried out in Italy and Spain, only few bird species seem to play a major role as blood donor for the mosquitoes [42,48,49]. Unfortunately, the reservoir competence for many European bird species is still unknown. Furthermore, mass mortality of highly susceptible species (such as corvids or other species) is less frequently observed in the Old than in the New World although some species, as the jackdaws (Corvus monedula) or other could potentially function as sentinel [50].

Virus persistence, silent circulation and spillover
Mechanisms of virus persistence in animal hosts in Europe are still unknown, but they could possibly lead to the development of persistent, chronic infections in certain individuals as seen in studies carried out in the United States [43,51]. In fact, in the New World, WNV, once established, circulates in enzootic cycles among few most competent mosquito species and their preferred feeding hosts [43,48,51]. The circulation of WNV in Europe may occur silently for several months, or even years, before the spillover event occurs [52]. One or more bird species may be involved in the amplification chain, some being important in the maintenance of the sylvatic cycles, while others (that might not be the same) may be involved in the periurban and urban cycles. Following spillover and following outbreak a subsidence phase may occur as a consequence of the rise of herd immunity in the reservoir birds, that is dependent on host longevity and the rate of recruitment of young individuals into the host population or the depopulation of highly susceptible bird hosts [43,51]. Unfortunately, the knowledge on herd immunity to WNV for many bird species of the Old World is still lacking.

WNV diversity and interactions with other flaviviruses
A wide spectrum of WNV lineages and strains with different potential pathogenicity and virulence thrive among other related flaviviruses with overlapping ecology such as Bagaza virus (BAGV) and Usutu virus (USUV)[52,53]. In this scenario, a previous infection of the WNV amplifying bird hosts with a low pathogenic strain of WNV or with a closely related flavivirus may confer some degree of cross-immunity which might reduce the amplification of any new WNV strain introduced into the same area [22]. This may explain, for instance, the scarcity of human WNV cases detected in Spain, where rates of WNV infection in birds are high and that may be due to the co-circulation of WNV lineage 6 [8] or other flaviviruses, that induce the production of potentially cross-protective antibodies in both humans and birds, as reported for example for USUV [54].

However, co-infection may occur also in the mosquito vectors and therefore WNV replication could be in some way affected by previous infection with other co-circulating flaviviruses of the same antigenic group or even more distant viruses so that the epidemiological picture may change from one site area to another [55]. Although some investigations on viral interference have been started with one project (EuroWestNile), we are still at the beginning of our understanding of the consequences of viral co-infections both in the host and in the vectors, and therefore research in this field is now of high interest.

Consequences for WNV surveillance in Europe
Passive surveillance programmes focusing only on the analysis of dead birds may fail to detect ongoing WNV circulation in Europe. It is advisable to combine conventional surveillance activities with actively monitoring seroconversion in sentinel and/or wild resident birds and horses [56-59].

Pathogenicity and other phenotypic traits

Studies using animal models, mainly mice, have provided insights into WNV pathogenesis. Intra-peritoneal injection of WNV into mice generally leads to encephalitis and other neurological signs resembling those observed in humans with WNND [60]. This model provides researchers with a simple method enabling phenotypic characterisation of WNV strains for neuropathogenicity and neuroinvasiveness. Through the integration of this information with analysis of genetic changes occurring in field WNV isolates and reverse genetics using infectious clones, molecular chimeras or other strategies, it is possible to identify determinants of virulence [61-63]. However, the mouse model has important limitations and thus alternative animal models are highly desirable. An attempt of this kind, using one day old chickens, has recently been reported [64]. In addition, bird models of WNV infection provide information about the course of the infection in natural hosts [65 and references herein] and, consequently, about key aspects of WNV epidemiology.

Genetic changes in different geographic WNV variants might allow to identify the link with phenotypic traits related to virulence, amplification, transmissibility to mosquitoes, and/or persistence, expressed in infected birds. Studies in avian models of WNV infection began in the US shortly after the first occurrence of WNV cases in 1999, and identified passerines as the group of birds developing higher and longer viraemias [66]. In contrast, studies testing the effect of European WNV strains in bird species indigenous to Europe have only been started recently [67-69].

Table 2 lists widely recognised genetic changes associated with virulence/attenuation, confirmed by viral cDNA clone mutagenesis/chimeras and using animal models of WNV infection [70-78]. Point mutations leading to amino acid changes either in structural (E) or non-structural (NS2A, NS3, NS4B) proteins result in attenuated phenotypes in different models. Pathogenicity appears also to be influenced by changes at both 5’ and 3’ non-coding regions. Interestingly, the WNV genome is relatively flexible as it can tolerate a number of changes in its sequence that do not seem to affect pathogenicity. However, generalisation of these findings could be misleading. The spectrum of WNV strains to which they can be applicable needs to be defined, as the phenotypic effect of each of the changes described for one given strain might not affect all WNV strains equally. Care should be exercised not to extend blindly the results observed in a given model to other susceptible species. For instance, the T249P mutation at the NS3 increases pathogenicity of a Kenyan WNV L1a strain for American crows (Corvus brachyrhynchos), and the opposite mutation reverts the high pathogenicity observed for the NY99 WNV strain in this species. However, this effect applies for American crows and not for house sparrows [79]. Moreover, Mediterranean WNV L1a strains with the NS3249P genotype did not show higher pathogenicity than their NS3249T counterparts either in mice [80], in the red-legged partridge (a bird species indigenous to southern Europe) [67], and in the house sparrow [68], although it has been recently shown that this mutation can modulate WNV pathogenicity of certain Mediterranean WNV strains for the European corvid, Corvus corone (carrion crow) [81]. Interestingly, the Greek WNV lineage 2 strains from the outbreaks in 2010 and 2011, involving human morbidity and mortality, have been shown to bear the NS3249P, contrary to their likely precursors from central Europe and the WNV strains that caused outbreaks in Serbia and in Italy, which have a histidine residue instead of proline at this site [58]. Despite suggestive, the association between the high pathogenicity observed in human outbreaks and the presence of NS3249P in these Greek lineage 2 WNV strains need to be assessed experimentally. Also, phenotypic assessment of WNV strains should not be limited to pathogenicity but should take in consideration other phenotypic traits, such as host competence (capacity of a given host species to transmit the virus efficiently to a mosquito feeding on its blood)/transmissibility. Variations in host competence have been reported for different WNV strains in the house sparrow [68,69], which might help to explain, at least in part, the different epidemiological patterns observed in the New versus the Old World.

Table 2. Non-exhaustive list of genetic determinants of West Nile virus pathogenicity identified in animal models


The laboratory diagnosis of acute WNV infection is based on both the detection of WNV RNA in blood and cerebrospinal fluid (CSF) or virus isolation in cell culture from serum samples (direct diagnosis) and on the demonstration of a specific immune response against the virus (indirect diagnosis), recently reviewed by [82] and [83].

Detection of viral RNA
Detection of WNV RNA in biological specimens represents a rapid method to unambiguously prove the infection with WNV [84]. Different PCR-based protocols have been developed to amplify minimal amounts of WNV RNA [85]. However, viraemia is short-lived in dead-end hosts and already declining substantially once the symptoms begin. Hence, detection of viral genomes becomes increasingly challenging over time. As a consequence, WNV RNA is generally not detectable in the blood of patients with symptomatic infection [86]. Additionally highly sensitive nucleic acid amplification-based methods may rarely provide false-positive results by cross-reaction with other flaviviruses [87]. Figure 3 delineates a timeline of clinical and diagnostic markers during human WNV infection.

Figure 3. Viraemia and humoral immune responses against West Nile virus 

Recent data demonstrated that WNV RNA can be detected in urine much longer and at higher concentrations than in blood or CSF in individuals with WNF or WNND [86,88]. The duration of WNV RNA detection in urine seems dependent on the course of disease and could last for 20 days or longer [86].

Similar results were observed in experimentally infected monkeys and hamsters [89,90]. The virus excreted in urine is infectious, since it can be isolated in cell culture from urine specimens collected from patients with acute infection [91].

Implementation of WNV RNA testing and isolation from urine samples in routine protocols for WNV diagnosis demonstrated the utility of these tests for the confirmation of cases [30,86,88,91]. Although PCR methods have been developed to detect both major WNV lineages [92], a first external quality assessment (EQA) study in 2006, revealed that many laboratories had problems in detecting genomes of WNV lineage 2 [93], an issue of high concern since lineage 1 and 2 viruses are co-circulating in Europe. In a recent second EQA in 2011, the participating laboratories had improved significantly regarding this aspect [87]. PCR multiplexing can be useful in this respect, and recently a multiplex PCR method able to detect and differentiate WNV lineages 1 and 2 and USUV has been developed [94]. It is also essential that current PCR methods are constantly being checked and updated for their sensitivity and suitability to detect newly emerging WNV strains to cope with the observed genetic variability of European WNV strains.

Antibody detection
Antibodies against WNV start to appear about four to seven days following infection and IgM antibodies are already detectable at early time points after symptoms onset [86] (Figure 3). Thus, the diagnosis of WNV infection generally relies on the demonstration of specific antibodies against WNV in serum or CSF.

The major problem with most serological diagnostic tests for WNV is cross-reactivity with infections caused by other flaviviruses, and the last EQA on WNV serology organised by the European Network for Diagnostics of Imported Viral Diseases (ENIVD) also showed the limits and needs for improvement [95]. Therefore, considerable effort is being made to develop antigens and/or test formats which can be used for specific detection of anti-WNV antibodies [reviewed in 83]. These also have to take into consideration the heterogeneity of human antibody profiles to WNV infection [96]. Furthermore, several flaviviruses have been found in areas affected by WNV, including BAGV, tick-borne encephalitis virus TBEV , and USUV [22,53,97,98].

Taking into account these problems, the European Union case definition for WNV infections demands confirmation in cases with IgM detection in serum by virus neutralisation test (VNT) [99], which today is the gold standard diagnostic method for flavivirus serology (reviewed in [83]). However, VNTs are time-consuming and require a biosafety level (BSL)-3 laboratory. Monoclonal antibody panels with strong and specific reactivity to TBEV, USUV and WNV were recently developed [100], which will likely enable the development of improved immunoassays for the detection and differentiation of flavivirus infections. Furthermore, monoclonal antibodies could be used for the development of competitive tests for the detection of different types of anti-WNV antibodies suitable for the range of WNV host species, including many species of wild birds and susceptible mammals [101]. Alternatively, the use of mutant forms of viral proteins leads to a minimisation of antibody cross-reactivity and enables the serological differentiation of flavivirus infections [102].


The persistent long-term effects seen after resolution of acute WNV infection in humans, the emerging threat that WNV poses to Europe and the placement of WNV on the list of bioterrorism agents, makes the development of a safe and effective vaccine for humans an urgent priority [103]. In fact, while several vaccines are already available for horses [104-106] and other currently under development due to the impact of WNV infection on the horse industry, no vaccine is available for humans.

Towards the production of a human vaccine
The increasing understanding of WNV pathogenesis and correlates of protection in animal models pave the way to a more rational design of candidate vaccines. Studies performed in mice elucidated some of the mechanisms of protection, such as the role of the adaptive immune responses in mitigating and preventing development of disease. This is exemplified by the observation that transfer of WNV-specific antibodies to naïve mice protected the animals against development of severe neurological disease [107]. Several lines of evidence indicate that the B cell response after infection with WNV is predominantly directed to non-neutralising epitopes located in domain I and II of glycoprotein E. The most potent neutralising epitopes are located in domain III (the receptor-binding ligand). For the development of a WNV vaccine for humans it is important to understand how vaccination could increase the longevity of B cells that produce these potent neutralising antibodies. As the probability of neuroinvasion in the animal host appeared to correlate with the level and duration of viraemia, it is conceivable that persistence of neutralising antibodies is sufficient to protect against severe disease [108]. Although T cells play a role in eliminating an established infection, thereby reducing the antigen load, it is believed that antibodies are more important for vaccine-induced protection. It is worth noting that both CD4+ and CD8+ T cells have been shown to contribute to control of WNV infection in animal models but it cannot be excluded that T cells may also cause disease [109].

Several platforms have been used to develop candidate vaccines against WNV for humans [109]. Various vaccine candidates have been shown to be highly effective in preventing fatal disease in mice and horses [110-112]. Long-term immunogenicity and safety, however, are some of the most important problems in current veterinary vaccines against WNV and potential candidates for use in humans. The regulatory authorities as well as public opinion demand safe and well characterised vaccines. Therefore, an effective WNV vaccine should stimulate protective and long-term immunity, preferably after a single dose, and should be free of significant side effects, especially in the elderly and immunocompromised individuals. Research on the use of several platforms for development of a safe and effective vaccine against WNV lineages 1 and 2 was an important topic in several European consortia and yielded promising candidate approaches.

Knowledge gaps and research priorities

Although significant progress in the scientific knowledge on WNV in Europe has been made through projects funded by the FP7, several knowledge gaps still limit our ability to properly forecast changes in the risks of outbreaks to occur or to prevent and control virus transmission to humans and animals.

Knowledge gaps on the introduction and spread of WNV in Europe
Our knowledge on how, when and from where WNV is introduced into Europe is still very limited today. The role of migrating birds on WNV translocations is recognised, however, many important questions still remain unanswered e.g. the geographic origin of each introduction of WNV into Europe, the relative importance of the introduction of infected vectors rather than infected birds, and the detailed transmission mechanisms involved in virus establishment into new  areas. For these reasons, better knowledge on the WNV ecology, vectors and virus strains circulating currently in Africa will be of utmost importance. Key factors leading to virus amplification and spread to neighbouring areas are also essentially unknown. Furthermore, we know that the virus may disappear from a previously infected area but we ignore the key factors leading to its extinction. Spillover events are increasing in numbers and expand geographically over time in Europe, however, our knowledge on the factors triggering such events continues to be rather poor. We do not know in most cases which are the key amplifying bird host and the bridge vector species involved. Moreover, we do not know the consequences of interventions such as massive culling of species considered as ‘pests’ and the contribution of factors such as species community composition under variable climatic and environmental conditions at local level. With this level of eco-epidemiological uncertainty, building-up accurate predictive models of WNV outbreak risk is a complex undertaking, although progress has been made in this direction [46,47,113]. Epidemiological models rely on good knowledge on basic epidemiological information of the virus and the disease it causes, which is still lacking in many cases, as outlined above. Filling this gap will not be an easy task; for instance, competence for WNV transmission of each host and vector species must be calculated experimentally for each viral strain, but given the heterogeneity of WNV found in Europe, this work will require a huge effort even if restricted to few representative strains and host/vector species.

Knowledge gaps on the impact of the presence of other flaviviruses on WNV epidemiology
Another important knowledge gap is the impact that other co-circulating flaviviruses (and perhaps arboviruses) may have on WNV epidemiology in Europe. Cross-immunity between closely related flaviviruses might lead to some degree of cross-protection in the animal hosts, or, even enhance infection in certain cases. Further assessment of the consequences of viral interference on the immune response both in hosts and vectors in Europe is needed. Realistic WNV models should also incorporate these effects. The diversity of flaviviruses circulating in Europe, including mosquito-only flaviviruses as well as newly emerging flavivirus strains, represent another challenge for WNV research. Europe’s preparedness to face emerging flavivirus threats depends largely on the availability of large datasets integrating genomic characterisation and analysis of all the strains isolated in Europe and neighbouring areas, including Africa. These datasets, together with the already started bank of viral strains, will be of paramount importance for the development of efficient molecular tools enabling proper flavivirus detection, identification and classification, along with studies on the origins of the different flaviviruses emerging in Europe and their evolutionary history.

Knowledge gaps on mosquito control
There is a need to strengthen the entomological capacity in Europe to improve surveillance, and risk assessment, and to identify the most appropriate and environmental friendly control strategies especially within hot spots of arbovirus emergence and spread in the Old World. The number of products available for mosquito control has been reduced in recent years. New insecticides and repellents are urgently needed since those available are losing efficacy. There is a clear need to define and evaluate the effectiveness of integrated mosquito control strategies and involve the public in mosquito source reduction. Models to support decision in mosquito control and management are also urgently required.

Knowledge gaps on the identification of virulence factors
Virus strain characterisation, in particular, virulence studies and identification of virulence determinants demand proper experimental animal models. Rodents (mice, hamsters) used as surrogate incidental mammal host model still need some standardisation and the same applies to wild birds, used as susceptible, reservoir and amplification host models useful to obtain data on virus pathogenicity and transmission. Suitable animal models would not only constitute an invaluable tool for virus characterisation, but also enable studies on co-infection, cross-protection, vaccine efficacy, therapeutic testing, the effect of stress and immunosuppression during the course of infection, among others.

Knowledge gaps on laboratory detection
The challenge in diagnostics is the WNV diversity in Europe and the need to continuously check the effectiveness of existing laboratory tests for the detection of newly arising strains or antibodies to them. This requires a considerable effort from all WNV diagnostic laboratories involved. The main gap in WNV serology is to develop new generation immunoassays avoiding cross-reactions with different flaviviruses and enabling good flavivirus differentiation, minimising the need for confirmation by the gold standard VNT. For that, large panels of well-characterised monoclonal antibodies to different flaviviral epitopes would be invaluable. Development of markers of early/mature immune response is also desirable. In the veterinary field, serological tests differentiating infected from vaccinated individuals are largely awaited. Where possible, inclusion of different types of antigens in the immunoassays would help to avoid false negative results due to heterogeneity of the humoral immune responses to WNV. In molecular diagnostics, new methods enabling rapid differential diagnosis of flavivirus infections, preferably in multiplex formats, are needed. New samples for virus detection and isolation (for instance, urine in humans, or feathers in wild bird surveillance) need further validation to assess their impact on diagnostic sensitivity and specificity, also, when possible, with different WNV strains.

Knowledge gaps on therapy and prevention
The lack of specific treatment and of human vaccines constitutes another gap in the mitigation of WNND. Together with the high susceptibility of the elderly, this renders the disease of great societal impact because of the ageing of the European population. The spread of WNV, even in the absence of clinical cases of WNND, imposes a significant economic burden for European public health due to the need to guarantee blood and organ transplantation safety.

Gaps in vaccine development include safety issues, especially in target susceptible populations such as the elderly and immunocompromised individuals. Due to the unpredictable regional spread of WNV outbreaks, clinical effectiveness testing of WNV vaccines in humans seems difficult. In combination with the yet limited market size, this has so far prevented further development of vaccine candidates by the pharmaceutical industry. Therefore, in order to move one or more of the existing (and promising) candidate vaccines towards clinical development, there needs to be a joint evaluation between industry, researchers and regulatory authorities. The possible interactions with other available flavivirus vaccines in Europe such as the ones against TBE and yellow fever virus (the latter only used for travellers to endemic areas outside Europe), and interactions with infections by other related flaviviruses, including cross-protection and/or antibody-dependent enhancement of infection, need further clarification.


The unpredictability of the West Nile virus risk for Europe and neighbouring countries is strongly linked to the knowledge gaps on many aspects of its complex ecology, genomic diversity, pathogenicity, transmissibility, diagnosis and control options, under different environmental and socio-economic scenarios. Therefore, there is an urgent need to intensify and continue the research efforts on WNV and other emerging vector-borne infections built under the FP7. In parallel, there is a growing need for a unified, harmonised, real-time epidemiological surveillance of WNV in vectors, humans and animals, especially within hot spots of virus circulation in Europe under the guidance of ECDC and other international organisations.

This paper is dedicated to the memory of our wonderful colleague and friend, Dr Paolo Cordioli, who recently passed away. We thank the European Centre for Disease Prevention and Control (ECDC) for supporting this initiative and for promoting a stronger integration between public health and research in Europe. We also thank Dr Jolanta Kolodziejek of the Institute of Virology, University of Veterinary Medicine Vienna for establishing the phylogenetic trees and Matteo Marcantonio of the GIS/RS platform at the Edmund Mach Foundation for preparing the map in Figure 1. This paper is the product of a cooperative action promoted by the Coordinators and delegates of the EU funded projects on West Nile virus under the 7th European Programme, in particular the EuroWestNile project (, GA n. 261391), the EDENext project ( , GA n. 261504) the Wings project ( , GA n. 261426), and the Vectorie project ( , GA n. 261466). This study was partially funded by EU grant FP7-261504 EDENext and is catalogued by the EDENext Steering Committee as EDENext 142 ( AR was partially funded by the Autonomous Province of Trento grant LExEM ( The contents of this publication are the sole responsibility of the authors and don't necessarily reflect the views of the European Commission.

Conflict of interest
None declared.

Authors’ contributions
AT conceived and coordinated the various contribution to the manuscript; AR and MAJC coordinated, wrote, reviewed and edited the final version of the manuscript; AR, AT, LB, NN, and MAJC drafted the contribution on virology and epidemiology; AR and JF drafted the contribution on ecology; NP, MAJC and PK drafted the contribution on pathogenesis; LB, SU, PC and AM drafted the contribution on diagnosis; BM and NS drafted the contribution on vaccine; AR and MAJC drafted the contribution on knowledge gaps. All contributors participated in the final revision of the manuscript.

This designation is without prejudice to positions on status, and is in line with United Nations Security Council Resolution 1244/99 and the International Court of Justice Opinion on the Kosovo declaration of independence.


  1. Zeller HG, Schuffenecker I. West Nile virus: an overview of its spread in Europe and the Mediterranean basin in contrast to its spread in the Americas. Eur J Clin Microbiol Infect Dis. 2004;23(3):147-56. PMID:14986160
  2. Sambri V, Capobianchi M, Charrel R, Fyodorova M, Gaibani P, Gould E, et al. West Nile virus in Europe: emergence, epidemiology, diagnosis, treatment, and prevention. Clin Microbiol Infect. 2013;19(8):699-704. PMID:23594175
  3. Paty MC. [The expansion of vector-borne diseases and the implications for blood transfusion safety: The case of West Nile Virus, dengue and chikungunya]. Transfus Clin Biol. 2013;20(2):165-73. PMID:23622840
  4. Vézilier J, Nicot A, Lorgeril J, Gandon S, Rivero A. The impact of insecticide resistance on Culex pipiens immunity. Evol Appl. 2013;6(3):497-509. PMID:23745141
  5. Bakonyi T, Ivanics E, Erdélyi K, Ursu K, Ferenczi E, Weissenböck H, et al. Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe. Emerg Infect Dis. 2006;12(4):618-23. PMID:16704810
  6. Bakonyi T, Hubálek Z, Rudolf I, Nowotny N. Novel flavivirus or new lineage of West Nile virus, central Europe. Emerg Infect Dis. 2005;11(2):225-31. PMID:15752439
  7. Lvov DK, Butenko AM, Gromashevsky VL, Kovtunov AI, Prilipov AG, Kinney R, et al. West Nile virus and other zoonotic viruses in Russia: examples of emerging-reemerging situations. Arch Virol Suppl. 2004;18(18):85-96. PMID:15119764
  8. Vázquez A, Sánchez-Seco MP, Ruiz S, Molero F, Hernández L, Moreno J, et al. Putative new lineage of west nile virus, Spain. Emerg Infect Dis. 2010;16(3):549-52. PMID:20202444
  9. Pachler K, Lebl K, Berer D, Rudolf I, Hubalek Z, Nowotny N. Putative new West Nile virus lineage in Uranotaenia unguiculata mosquitoes, Austria, 2013. Emerg Infect Dis. 2014;20(12):2119-22. PMID:25418009
  10. Fall G, Diallo M, Loucoubar C, Faye O, Sall AA. Vector competence of Culex neavei and Culex quinquefasciatus (Diptera: Culicidae) from Senegal for lineages 1, 2, Koutango and a putative new lineage of West Nile virus. Am J Trop Med Hyg. 2014;90(4):747-54. PMID:24567319
  11. Bakonyi T, Ivanics E, Erdélyi K, Ursu K, Ferenczi E, Weissenböck H, et al. Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe. Emerg Infect Dis. 2006;12(4):618-23. Infect Dis. PMID:16704810
  12. Bakonyi T, Ferenczi E, Erdélyi K, Kutasi O, Csörgő T, Seidel B, et al. Explosive spread of a neuroinvasive lineage 2 West Nile virus in Central Europe, 2008/2009. Vet Microbiol. 2013;165(1-2):61-70. PMID:23570864
  13. Platonov AE, Karan’ LS, Shopenskaia TA, Fedorova MV, Koliasnikova NM, Rusakova NM, et al. [Genotyping of West Nile fever virus strains circulating in southern Russia as an epidemiological investigation method: principles and results]. Zh Mikrobiol Epidemiol Immunobiol. 2011; (2):29-37. Russian. PMID:21598612
  14. Sirbu A, Ceianu CS, Panculescu-Gatej RI, Vazquez A, Tenorio A, Rebreanu R, et al. Outbreak of West Nile virus infection in humans, Romania, July to October 2010. Euro Surveill. 2011;16(2):19762. PMID:21251489
  15. Kolodziejek J, Marinov M, Kiss BJ, Alexe V, Nowotny N. The complete sequence of a West Nile virus lineage 2 strain detected in a Hyalomma marginatum marginatum tick collected from a song thrush (Turdus philomelos) in Eastern Romania in 2013 revealed closest genetic relationship to strain Volgograd 2007. PLoS One. 2014 Oct 3;9(10):e109905. doi: 10.1371/journal.pone.0109905. eCollection 2014.
  16. May FJ, Davis CT, Tesh RB, Barrett AD. Phylogeography of West Nile virus: from the cradle of evolution in Africa to Eurasia, Australia, and the Americas. J Virol. 2011;85(6):2964-74. PMID:21159871
  17. Zehender G, Ebranati E, Bernini F, Lo Presti A, Rezza G, Delogu M, et al. Phylogeography and epidemiological history of West Nile virus genotype 1a in Europe and the Mediterranean basin. Infect Genet Evol. 2011;11(3):646-53. PMID:21320643
  18. Pybus OG, Suchard MA, Lemey P, Bernardin FJ, Rambaut A, Crawford FW, et al. Unifying the spatial epidemiology and molecular evolution of emerging epidemics. Proc Natl Acad Sci USA. 2012;109(37):15066-71. PMID:22927414
  19. Barzon L, Pacenti M, Franchin E, Martello T, Lavezzo E, Squarzon L, et al. Clinical and virological findings in the ongoing outbreak of West Nile virus Livenza strain in northern Italy, July to September 2012. Euro Surveill. 2012;17(36):20260. PMID:22971328
  20. Sotelo E, Fernández-Pinero J, Llorente F, Vázquez A, Moreno A, Agüero M, et al. Phylogenetic relationships of Western Mediterranean West Nile virus strains (1996-2010) using full-length genome sequences: single or multiple introductions? J Gen Virol. 2011a;92(11):2512-22. PMID:21775579
  21. Pesko KN, Ebel GD. West Nile virus population genetics and evolution. Infect Genet Evol. 2012;12(2):181-90. PMID:22226703
  22. Beck C, Jimenez-Clavero MA, Leblond A, Durand B, Nowotny N, Leparc-Goffart I, et al. Flaviviruses in Europe: complex circulation patterns and their consequences for the diagnosis and control of West Nile disease. Int J Environ Res Public Health. 2013;10(11):6049-83. PMID:24225644
  23. Papa A, Bakonyi T, Xanthopoulou K, Vázquez A, Tenorio A, Nowotny N. Genetic characterization of West Nile virus lineage 2, Greece, 2010. Emerg Infect Dis. 2011;17(5):920-2. PMID:21529413
  24. Barzon L, Papa A, Pacenti M, Franchin E, Lavezzo E, Squarzon L, et al. Genome sequencing of West Nile Virus from human cases in Greece, 2012. Viruses. 2013;5(9):2311-9. PMID:24064795
  25. Popović N, Milošević B, Urošević A, Poluga J, Lavadinović L, Nedelijković J, et al. Outbreak of West Nile virus infection among humans in Serbia, August to October 2012. Euro Surveill. 2013;18(43):20613. PMID:24176618
  26. Petrović T, Blazquez AB, Lupulović D, Lazić G, Escribano-Romero E, Fabijan D, et al. Monitoring West Nile virus (WNV) infection in wild birds in Serbia during 2012: first isolation and characterisation of WNV strains from Serbia. Euro Surveill. 2013;18(44):20622. PMID:24176657
  27. Kemenesi G, Krtinić B, Milankov V, Kutas A, Dallos B, Oldal M, et al. West Nile virus surveillance in mosquitoes, April to October 2013, Vojvodina province, Serbia: implications for the 2014 season. Euro Surveill. 2014;19(16):20779. PMID:24786260
  28. Stiasny K, Aberle SW, Heinz FX. Retrospective identification of human cases of West Nile virus infection in Austria (2009 to 2010) by serological differentiation from Usutu and other flavivirus infections. Euro Surveill. 2013;18(43):20614. PMID:24176619
  29. Pem-Novosel I, Vilibic-Cavlek T, Gjenero-Margan I, Pandak N, Peric L, Barbic L, et al. First outbreak of West Nile virus neuroinvasive disease in humans, Croatia, 2012. Vector Borne Zoonotic Dis. 2014;14(1):82-4. PMID:24283515
  30. Kurolt IC, Krajinović V, Topić A, Kuzman I, Baršić B, Markotić A. First molecular analysis of West Nile virus during the 2013 outbreak in Croatia. Virus Res. 2014;189:63-6. PMID:24809948
  31. Savini G, Capelli G, Monaco F, Polci A, Russo F, Di Gennaro A, et al. Evidence of West Nile virus lineage 2 circulation in Northern Italy. Vet Microbiol. 2012;158(3-4):267-73. PMID:22406344
  32. Bagnarelli P, Marinelli K, Trotta D, Monachetti A, Tavio M, Del Gobbo R, et al. Human case of autochthonous West Nile virus lineage 2 infection in Italy, September 2011. Euro Surveill. 2011;16(43):20002. PMID:22085600
  33. Magurano F, Remoli ME, Baggieri M, Fortuna C, Marchi A, Fiorentini C, et al. Circulation of West Nile virus lineage 1 and 2 during an outbreak in Italy. Clin Microbiol Infect. 2012;18(12):E545-7. PMID:23020657
  34. Barzon L, Pacenti M, Franchin E, Lavezzo E, Masi G, Squarzon L, et al. Whole genome sequencing and phylogenetic analysis of West Nile virus lineage 1 and lineage 2 from human cases of infection, Italy, August 2013. Euro Surveill. 2013;18(38):20591. PMID:24084339
  35. Rudolf I, Bakonyi T, Sebesta O, Mendel J, Peško J, Betášová L, et al. West Nile virus lineage 2 isolated from Culex modestus mosquitoes in the Czech Republic, 2013: expansion of the European WNV endemic area to the North? Euro Surveill. 2014;19(31):2-5. PMID:25138970
  36. Barzon L, Pacenti M, Franchin E, Squarzon L, Lavezzo E, Cattai M, et al. The complex epidemiological scenario of West Nile virus in Italy. Int J Environ Res Public Health. 2013;10(10):4669-89. PMID:24084676
  37. Barzon L, Pacenti M, Franchin E, Pagni S, Lavezzo E, Squarzon L, et al. Large human outbreak of West Nile virus infection in north-eastern Italy in 2012. Viruses. 2013;5(11):2825-39. PMID:24284876
  38. Kalaycioglu H, Korukluoglu G, Ozkul A, Oncul O, Tosun S, Karabay O, et al. Emergence of West Nile virus infections in humans in Turkey, 2010 to 2011. Euro Surveill. 2012;17(21):20182. PMID:22687827
  39. Ergunay K, Bakonyi T, Nowotny N, Ozkul A. Close relationship between West Nile virus from Turkey and lineage 1 strain from Central African Republic. Emerg Infect Dis. 2015;21(2):352-5. PMID:25625703
  40. Kopel E, Amitai Z, Bin H, Shulman LM, Mendelson E, Sheffer R. Surveillance of West Nile virus disease, Tel Aviv district, Israel, 2005 to 2010. Euro Surveill. 2011;16(25):19894. PMID:21722612
  41. Engler O, Savini G, Papa A, Figuerola J, Groschup MH, Kampen H, et al. European surveillance for West Nile virus in mosquito populations. Int J Environ Res Public Health. 2013;10(10):4869-95. PMID:24157510
  42. Muñoz J, Ruiz S, Soriguer R, Alcaide M, Viana DS, Roiz D, et al. Feeding patterns of potential West Nile virus vectors in south-west Spain. PLoS ONE. 2012;7(6):e39549. PMID:22745781
  43. Reisen WK. Ecology of West Nile virus in North America. Viruses. 2013;5(9):2079-105. PMID:24008376
  44. López G, Jiménez-Clavero MA, Vázquez A, Soriguer R, Gómez-Tejedor C, Tenorio A, et al. Incidence of West Nile virus in birds arriving in wildlife rehabilitation centers in southern Spain. Vector Borne Zoonotic Dis. 2011;11(3):285-90. PMID:20645867
  45. Figuerola J, Jiménez-Clavero MA, López G, Rubio C, Soriguer R, Gómez-Tejedor C, et al. Size matters: West Nile Virus neutralizing antibodies in resident and migratory birds in Spain. Vet Microbiol. 2008;132(1-2):39-46. PMID:18514437
  46. Paz S, Semenza JC. Environmental drivers of West Nile fever epidemiology in Europe and Western Asia--a review. Int J Environ Res Public Health. 2013;10(8):3543-62. PMID:23939389
  47. Paz S, Malkinson D, Green MS, Tsioni G, Papa A, Danis K, et al. Permissive summer temperatures of the 2010 European West Nile fever upsurge. PLoS ONE. 2013;8(2):e56398. PMID:23431374
  48. Hamer GL, Kitron UD, Goldberg TL, Brawn JD, Loss SR, Ruiz MO, et al. Host selection by Culex pipiens mosquitoes and West Nile virus amplification. Am J Trop Med Hyg. 2009;80(2):268-78. PMID:19190226
  49. Roiz D, Vazquez A, Rosà R, Muñoz J, Arnoldi D, Rosso F, et al. Blood meal analysis, flavivirus screening, and influence of meteorological variables on the dynamics of potential mosquito vectors of West Nile virus in northern Italy. J Vector Ecol. 2012;37(1):20-8. PMID:22548533
  50. Lim SM, Brault AC, van Amerongen G, Sewbalaksing VD, Osterhaus AD, Martina BE, et al. Susceptibility of European jackdaws (Corvus monedula) to experimental infection with lineage 1 and 2 West Nile viruses. J Gen Virol. 2014;95(Pt_6):1320-9. PMID:24671752
  51. Kwan JL, Kluh S, Reisen WK. Antecedent avian immunity limits tangential transmission of West Nile virus to humans. PLoS ONE. 2012;7(3):e34127. PMID:22457819
  52. Weissenböck H, Bakonyi T, Rossi G, Mani P, Nowotny N. Usutu virus, Italy, 1996. Emerg Infect Dis. 2013;19(2):274-7. PMID:23347844
  53. Agüero M, Fernández-Pinero J, Buitrago D, Sánchez A, Elizalde M, San Miguel E, et al. Bagaza virus in partridges and pheasants, Spain, 2010. Emerg Infect Dis. 2011;17(8):1498-501. 10.3201/eid1708.110077 PMID:21801633
  54. Bakonyi T, Busquets N, Nowotny N. Comparison of complete genome sequences of Usutu virus strains detected in Spain, Central Europe, and Africa. Vector Borne Zoonotic Dis. 2014;14(5):324-9. PMID:24746182
  55. Calzolari M, Zé-Zé L, Růžek D, Vázquez A, Jeffries C, Defilippo F, et al. Detection of mosquito-only flaviviruses in Europe. J Gen Virol. 2012;93(Pt_6):1215-25. PMID:22377581
  56. Figuerola J, Soriguer R, Rojo G, Gómez Tejedor C, Jímenez-Clavero MA. Seroconversion in wild birds and local circulation of West Nile virus, Spain. Emerg Infect Dis. 2007;13(12):1915-7. PMID:18258046
  57. Chaintoutis SC, Dovas CI, Papanastassopoulou M, Gewehr S, Danis K, Beck C, et al. Evaluation of a West Nile virus surveillance and early warning system in Greece, based on domestic pigeons. Comp Immunol Microbiol Infect Dis. 2014;37(2):131-41. PMID:24503179
  58. Calzolari M, Monaco F, Montarsi F, Bonilauri P, Ravagnan S, Bellini R, et al. New incursions of West Nile virus lineage 2 in Italy in 2013: the value of the entomological surveillance as early warning system. Vet Ital. 2013;49(3):315-9. PMID:24002939
  59. Rizzoli A, Rosà R, Rosso F, Buckley A, Gould E. West Nile virus circulation detected in northern Italy in sentinel chickens. Vector Borne Zoonotic Dis. 2007;7(3):411-7. PMID:17767411
  60. Beasley DW, Davis CT, Whiteman M, Granwehr B, Kinney RM, Barrett AD. Molecular determinants of virulence of West Nile virus in North America. Arch Virol Suppl. 2004; (18):35-41. PMID:15119761
  61. Beasley DW, Whiteman MC, Zhang S, Huang CY, Schneider BS, Smith DR, et al. Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J Virol. 2005;79(13):8339-47. PMID:15956579
  62. Audsley M, Edmonds J, Liu W, Mokhonov V, Mokhonova E, Melian EB, et al. Virulence determinants between New York 99 and Kunjin strains of West Nile virus. Virology. 2011;414(1):63-73. PMID:21477835
  63. Donadieu E, Lowenski S, Servely JL, Laloy E, Lilin T, Nowotny N, et al. Comparison of the neuropathology induced by two West Nile virus strains. PLoS ONE. 2013;8(12):e84473. PMID:24367664
  64. Dridi M, Rauw F, Muylkens B, Lecollinet S, van den Berg T, Lambrecht B. Setting up a SPF chicken model for the pathotyping of West Nile virus (WNV) strains. Transbound Emerg Dis. 2013;60(Suppl 2):51-62. PMID:24589102
  65. Pérez-Ramírez E, Llorente F, Jiménez-Clavero MÁ. Experimental infections of wild birds with West Nile virus. Viruses. 2014;6(2):752-81. PMID:24531334
  66. Komar N, Langevin S, Hinten S, Nemeth N, Edwards E, Hettler D, et al. Experimental infection of North American birds with the New York 1999 strain of West Nile virus. Emerg Infect Dis. 2003;9(3):311-22. PMID:12643825
  67. Sotelo E, Gutierrez-Guzmán AV, del Amo J, Llorente F, El-Harrak M, Pérez-Ramírez E, et al. Pathogenicity of two recent Western Mediterranean West Nile virus isolates in a wild bird species indigenous to Southern Europe: the red-legged partridge. Vet Res. 2011b;42(1):11. PMID:21314967
  68. Del Amo J, Llorente F, Figuerola J, Soriguer RC, Moreno AM, Cordioli P, et al. Experimental infection of house sparrows (Passer domesticus) with West Nile virus isolates of Euro-Mediterranean and North American origins. Vet Res. 2014; 19:45:33. doi: 10.1186/1297-9716-45-33.
  69. Del Amo J, Llorente F, Pérez-Ramirez E, Soriguer RC, Figuerola J, Nowotny N, et al. Experimental infection of house sparrows (Passer domesticus) with West Nile virus strains of lineages 1 and 2. Vet Microbiol. 2014;172(3-4):542-7. PMID:24984945
  70. Beasley DW, Davis CT, Whiteman M, Granwehr B, Kinney RM, Barrett AD. Molecular determinants of virulence of West Nile virus in North America. Arch Virol Suppl. 2004; (18):35-41. PMID:15119761
  71. Beasley DW, Whiteman MC, Zhang S, Huang CY, Schneider BS, Smith DR, et al. Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J Virol. 2005;79(13):8339-47. PMID:15956579
  72. Melian EB, Hinzman E, Nagasaki T, Firth AE, Wills NM, Nouwens AS, et al. NS1′ of flaviviruses in the Japanese encephalitis virus serogroup is a product of ribosomal frameshifting and plays a role in viral neuroinvasiveness. J Virol. 2010;84(3):1641-7. PMID:19906906
  73. Liu WJ, Wang XJ, Clark DC, Lobigs M, Hall RA, Khromykh AA. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J Virol. 2006;80(5):2396-404. PMID:16474146
  74. Brault AC, Huang CY, Langevin SA, Kinney RM, Bowen RA, Ramey WN, et al. A single positively selected West Nile viral mutation confers increased virogenesis in American crows. Nat Genet. 2007;39(9):1162-6. PMID:17694056
  75. Wicker JA, Whiteman MC, Beasley DW, Davis CT, Zhang S, Schneider BS, et al. A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice. Virology. 2006;349(2):245-53. PMID:16624366
  76. Puig-Basagoiti F, Tilgner M, Bennett CJ, Zhou Y, Muñoz-Jordán JL, García-Sastre A, et al. A mouse cell-adapted NS4B mutation attenuates West Nile virus RNA synthesis. Virology. 2007;361(1):229-41. PMID:17178141
  77. Pijlman GP, Funk A, Kondratieva N, Leung J, Torres S, van der Aa L, et al. A highly structured, nuclease-resistant, noncoding RNA produced by flaviviruses is required for pathogenicity. Cell Host Microbe. 2008;4(6):579-91. PMID:19064258
  78. Audsley M, Edmonds J, Liu W, Mokhonov V, Mokhonova E, Melian EB, et al. Virulence determinants between New York 99 and Kunjin strains of West Nile virus. Virology. 2011;414(1):63-73. PMID:21477835
  79. Langevin SA, Brault AC, Panella NA, Bowen RA, Komar N. Variation in virulence of West Nile virus strains for house sparrows (Passer domesticus). Am J Trop Med Hyg. 2005; 72(1):99-102.80.
  80. Sotelo E, Fernandez-Pinero J, Llorente F, Agüero M, Hoefle U, Blanco JM, et al. Characterization of West Nile virus isolates from Spain: new insights into the distinct West Nile virus eco-epidemiology in the Western Mediterranean. Virology. 2009;395(2):289-97. PMID:19833373
  81. Dridi M, Vangeluwe D, Lecollinet S, van den Berg T, Lambrecht B. Experimental infection of Carrion crows (Corvus corone) with two European West Nile virus (WNV) strains. Vet Microbiol. 2013;165(1-2):160-6. PMID:23434187
  82. Hobson-Peters J. Approaches for the development of rapid serological assays for surveillance and diagnosis of infections caused by zoonotic flaviviruses of the Japanese encephalitis virus serocomplex. J Biomed Biotechnol. 2012;2012:379738. PMID:22570528
  83. De Filette M, Ulbert S, Diamond M, Sanders NN. Recent progress in West Nile virus diagnosis and vaccination. Vet Res. 2012;43(1):16. PMID:22380523
  84. Barzon L, Pacenti M, Cusinato R, Cattai M, Franchin E, Pagni S, et al. Human cases of West Nile Virus infection in north-eastern Italy, 15 June to 15 November 2010. Euro Surveill. 2011;16(33):19949. PMID:21871228
  85. Linke S, Ellerbrok H, Niedrig M, Nitsche A, Pauli G. Detection of West Nile virus lineages 1 and 2 by real-time PCR. J Virol Methods. 2007;146(1-2):355-8. PMID:17604132
  86. Barzon L, Pacenti M, Franchin E, Pagni S, Martello T, Cattai M, et al. Excretion of West Nile virus in urine during acute infection. J Infect Dis. 2013;208(7):1086-92. PMID:23821721
  87. Linke S, Mackay WG, Scott C, Wallace P, Niedrig M. Second external quality assessment of the molecular diagnostic of West Nile virus: are there improvements towards the detection of WNV? J Clin Virol. 2011;52(3):257-60. PMID:21893429
  88. Murray K, Walker C, Herrington E, Lewis JA, McCormick J, Beasley DW, et al. Persistent infection with West Nile virus years after initial infection. J Infect Dis. 2010;201(1):2-4. PMID:19961306
  89. Verstrepen BE, Fagrouch Z, van Heteren M, Buitendijk H, Haaksma T, Beenhakker N, et al. Experimental infection of rhesus macaques and common marmosets with a European strain of West Nile virus. PLoS Negl Trop Dis. 2014;8(4):e2797. PMID:24743302
  90. Tonry JH, Xiao S-Y, Siirin M, Chen H, da Rosa AP, Tesh RB. Persistent shedding of West Nile virus in urine of experimentally infected hamsters. Am J Trop Med Hyg. 2005;72(3):320-4. PMID:15772329
  91. Barzon L, Pacenti M, Franchin E, Squarzon L, Sinigaglia A, Ulbert S, et al. Isolation of West Nile virus from urine samples of patients with acute infection. J Clin Microbiol. 2014;52(9):3411-3. PMID:24951801
  92. Jiménez-Clavero MA, Agüero M, Rojo G, Gómez-Tejedor C. A new fluorogenic real-time RT-PCR assay for detection of lineage 1 and lineage 2 West Nile viruses. J Vet Diagn Invest. 2006;18(5):459-62. PMID:17037613
  93. Niedrig M, Linke S, Zeller H, Drosten C. First international proficiency study on West Nile virus molecular detection. Clin Chem. 2006;52(10):1851-4. PMID:16887901
  94. Del Amo J, Sotelo E, Fernández-Pinero J, Gallardo C, Llorente F, Agüero M, et al. A novel quantitative multiplex real-time RT-PCR for the simultaneous detection and differentiation of West Nile virus lineages 1 and 2, and of Usutu virus. J Virol Methods. 2013;189(2):321-7. PMID:23499258
  95. Sanchini A, Donoso-Mantke O, Papa A, Sambri V, Teichmann A, Niedrig M. Second international diagnostic accuracy study for the serological detection of West Nile virus infection. PLoS Negl Trop Dis. 2013;7(4):e2184. PMID:23638205
  96. Chabierski S, Makert GR, Kerzhner A, Barzon L, Fiebig P, Liebert UG, et al. Antibody responses in humans infected with newly emerging strains of West Nile Virus in Europe. PLoS ONE. 2013;8(6):e66507. PMID:23776680
  97. Llorente F, Pérez-Ramírez E, Fernández-Pinero J, Soriguer R, Figuerola J, Jiménez-Clavero MA. Flaviviruses in game birds, southern Spain, 2011-2012. Emerg Infect Dis. 2013;19(6):1023-5. PMID:23735195
  98. Rushton JO, Lecollinet S, Hubálek Z, Svobodová P, Lussy H, Nowotny N. Tick-borne encephalitis virus in horses, Austria, 2011. Emerg Infect Dis. 2013;19(4):635-7. PMID:23631894
  99. European Commission. Commission implementing decision of 8 August 2012 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. Official Journal of the European Union. Luxembourg: Publications Office of the European Union. 27.9.2012:L 262. Available from:
  100. Lelli D, Moreno A, Brocchi E, Sozzi E, Capucci L, Canelli E, et al. West Nile virus: characterization and diagnostic applications of monoclonal antibodies. Virol J. 2012;9(1):81. PMID:22500562
  101. Sotelo E, Llorente F, Rebollo B, Camuñas A, Venteo A, Gallardo C, et al. Development and evaluation of a new epitope-blocking ELISA for universal detection of antibodies to West Nile virus. J Virol Methods. 2011;174(1-2):35-41. PMID:21419800
  102. Chabierski S, Barzon L, Papa A, Niedrig M, Bramson JL, Richner JM, et al. Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop. BMC Infect Dis. 2014;14(1):246. PMID:24884467
  103. Martina BE, Koraka P, Osterhaus AD. West Nile Virus: is a vaccine needed? Curr Opin Investig Drugs. 2010;11(2):139-46. PMID:20112163
  104. Ng T, Hathaway D, Jennings N, Champ D, Chiang YW, Chu HJ. Equine vaccine for West Nile virus. Dev Biol (Basel). 2003;114:221-7. PMID:14677692
  105. El Garch H, Minke JM, Rehder J, Richard S, Edlund Toulemonde C, Dinic S, et al. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. Vet Immunol Immunopathol. 2008;123(3-4):230-9. PMID:18372050
  106. Dayan GH, Pugachev K, Bevilacqua J, Lang J, Monath TP. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses. 2013;5(12):3048-70. PMID:24351795
  107. Martina BE, van den Doel P, Koraka P, van Amerongen G, Spohn G, Haagmans BL, et al. A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus. PLoS ONE. 2011;6(4):e18995. PMID:21541326
  108. Diamond MS. Virus and host determinants of West Nile virus pathogenesis. PLoS Pathog. 2009;5(6):e1000452. PMID:19557199
  109. Wang Y, Lobigs M, Lee E, Müllbacher A. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol. 2003;77(24):13323-34. PMID:14645588
  110. Magnusson SE, Karlsson KH, Reimer JM, Corbach-Söhle S, Patel S, Richner JM, et al. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice. Vaccine. 2014;32(7):800-8. PMID:24380682
  111. De Filette M, Soehle S, Ulbert S, Richner J, Diamond MS, Sinigaglia A, et al. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. PLoS ONE. 2014;9(2):e87837. PMID:24503579
  112. Minke JM, Siger L, Cupillard L, Powers B, Bakonyi T, Boyum S, et al. Protection provided by a recombinant ALVAC(®)-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain. Vaccine. 2011;29(28):4608-12. PMID:21549780
  113. Rosà R, Marini G, Bolzoni L, Neteler M, Metz M, Delucchi L, et al. Early warning of West Nile virus mosquito vector: climate and land use models successfully explain phenology and abundance of Culex pipiens mosquitoes in north-western Italy. Parasit Vectors. 2014;7(1):269. PMID:24924622
  114. Lanciotti RS, Roehrig JT, Deubel V, Smith J, Parker M, Steele K, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science. 1999;286(5448):2333-7. PMID:10600742
  115. Coia G, Parker MD, Speight G, Byrne ME, Westaway EG. Nucleotide and complete amino acid sequences of Kunjin virus: definitive gene order and characteristics of the virus-specified proteins. J Gen Virol. 1988;69(1):1-21. PMID:2826659
  116. Bondre VP, Jadi RS, Mishra AC, Yergolkar PN, Arankalle VA. West Nile virus isolates from India: evidence for a distinct genetic lineage. J Gen Virol. 2007;88(3):875-84. PMID:17325360
  117. Smithburn KC, Hughs TP, Burke AW, Paul JH. A Neurotropic Virus Isolated from the Blood of a Native of Uganda. Am J Trop Med Hyg. 1940;20:471-92.
  118. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28(10):2731-9. PMID:21546353

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.